Hydroxychloroquine prophylaxis in preventing the severe forms of Covid-19

Phase 3

• Conditions: Covid-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200421047153N1
• Lead Sponsor: Islamic Azad University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

18-65 years old
No symptoms of corona and no positive corona test
The desire to participate in the study
No symptoms of disease at the time of admission
No positive test

Exclusion Criteria

History of allergy to hydroxychloroquine
Contraindications for drug use include previous history of retinopathy or G6PD, LONG QT SYNDROME, porphyry
Positive HIV patients
Patients with autoimmune diseases (lupus-rheumatoid arthritis)
BMI >40
Diabetic
CKD
Using medications with contraindication to use hydroxychloroquine

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of mild type covid-19 (fever - cough - dyspnea- positive PCRtest)-CDC. Timepoint: weekly for 10 weeks. Method of measurement: phone interview -medical record review.;Incidence of severe type (dyspnea - chest pain or pressure - decreased level of consciousness - bruising of the lips and face and positive PCR test) based on CDC definition. Timepoint: weekly for 10 weeks. Method of measurement: phone interview -medical record review.

Secondary Outcome Measures

Name	Time	Method
Hospitalization need. Timepoint: Weekly to 10 weeks. Method of measurement: phone interview -medical record review.;Mechanical ventilation need. Timepoint: Weekly to 10 weeks. Method of measurement: phone interview -medical record review.;Deaths. Timepoint: Weekly to 10 weeks. Method of measurement: phone interview -medical record review.